This site is intended for healthcare professionals outside the US.

In advanced, progressive, well-differentiated nonfunctional GI and lung NET

The RADIANT-4 population had a diverse range of patient characteristics1

Patient population of the RADIANT-4 study by primary site of tumor origin

Prognostic subgroups used in stratification

Patient population of the RADIANT-4 study by prognostic subgroups used in stratification

  • 80% of patients had received other prior anticancer treatment, including radiotherapy (21%), surgery (63%), locoregional therapy (11%), and antineoplastic medications (31%)3

Select demographic characteristics

Age1 Gender1 Race3
  • 53% <65 years of age
  • 47% >65 years of age
  • Median age=63 years
  • 53% female
  • 47% male
  • 76% Caucasian
  • 17% Asian
  • 5% Black
  • 2.3% Other
CUP, cancer of unknown primary; GI, gastrointestinal; NET, neuroendocrine tumor(s); PS, performance status; RADIANT, RAD001 in Advanced Neuroendocrine Tumors; SEER, Surveillance, Epidemiology, and End Results; SSA, somatostatin analogue; WHO, World Health Organization.
  1. Yao JC, Fazio N, Singh S, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2016;387(10022):968-977.
  2. Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063-3072.
  3. Data on file. Novartis Pharma AG.